• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Clinical predictors of treatment failure for diabetic foot infections: data from a prospective trial.糖尿病足感染治疗失败的临床预测因素:来自一项前瞻性试验的数据。
Int Wound J. 2007 Mar;4(1):30-8. doi: 10.1111/j.1742-481X.2006.00274.x.
2
Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial.厄他培南对比哌拉西林/他唑巴坦治疗糖尿病足感染(SIDESTEP):前瞻性、随机、对照、双盲、多中心试验
Lancet. 2005 Nov 12;366(9498):1695-703. doi: 10.1016/S0140-6736(05)67694-5.
3
Comparative costs of ertapenem and piperacillin-tazobactam in the treatment of diabetic foot infections.厄他培南与哌拉西林-他唑巴坦治疗糖尿病足感染的成本比较
Am J Health Syst Pharm. 2007 May 15;64(10):1080-6. doi: 10.1093/ajhp/64.10.1080.
4
Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK.在英国,评估厄他培南与哌拉西林/他唑巴坦治疗糖尿病足感染的成本效益时,需要考虑抗菌药物耐药性的发展。
Pharmacoeconomics. 2009;27(12):1045-56. doi: 10.2165/11310080-000000000-00000.
5
Ertapenem versus piperacillin/tazobactam for diabetic foot infections in China: a Phase 3, multicentre, randomized, double-blind, active-controlled, non-inferiority trial.厄他培南对比哌拉西林/他唑巴坦治疗中国糖尿病足感染:一项 3 期、多中心、随机、双盲、阳性药物对照、非劣效性临床试验。
J Antimicrob Chemother. 2016 Jun;71(6):1688-96. doi: 10.1093/jac/dkw004. Epub 2016 Feb 16.
6
Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention.厄他培南与哌拉西林-他唑巴坦治疗需要手术干预的腹腔内感染的疗效与安全性比较
J Gastrointest Surg. 2006 Apr;10(4):567-74. doi: 10.1016/j.gassur.2005.06.015.
7
Ertapenem versus piperacillin-tazobactam for treatment of mixed anaerobic complicated intra-abdominal, complicated skin and skin structure, and acute pelvic infections.厄他培南与哌拉西林-他唑巴坦治疗混合性厌氧性复杂性腹腔内感染、复杂性皮肤及皮肤结构感染和急性盆腔感染的比较
Surg Infect (Larchmt). 2002 Winter;3(4):303-14. doi: 10.1089/109629602762539535.
8
Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials.厄他培南与哌拉西林/他唑巴坦治疗复杂性感染:随机对照试验的荟萃分析。
BMC Infect Dis. 2009 Dec 2;9:193. doi: 10.1186/1471-2334-9-193.
9
Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate.与哌拉西林-他唑巴坦/阿莫西林-克拉维酸相比,序贯静脉注射至口服莫西沙星治疗糖尿病足感染。
J Antimicrob Chemother. 2007 Aug;60(2):370-6. doi: 10.1093/jac/dkm130. Epub 2007 Jun 6.
10
An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers.一项比较静脉注射哌拉西林/他唑巴坦与氨苄西林/舒巴坦治疗感染性糖尿病足溃疡的疗效和安全性的开放标签随机研究。
Surg Infect (Larchmt). 2005 Spring;6(1):27-40. doi: 10.1089/sur.2005.6.27.

引用本文的文献

1
Exploring the Microbiome of Diabetic Foot Ulcers: A Focus on Cases with a Clinical Worse Outcome.探索糖尿病足溃疡的微生物群:聚焦临床结局较差的病例
Antibiotics (Basel). 2025 Jul 18;14(7):724. doi: 10.3390/antibiotics14070724.
2
Predictive Factors of Amputation in Diabetic Foot.糖尿病足截肢的预测因素
Biomedicines. 2024 Dec 6;12(12):2775. doi: 10.3390/biomedicines12122775.
3
Analysis of factors influencing the recurrence of diabetic foot ulcers.分析影响糖尿病足溃疡复发的因素。
Skin Res Technol. 2024 Jul;30(7):e13826. doi: 10.1111/srt.13826.
4
The Efficacy of Diabetic Foot Treatment in a "TOSF" Pattern: A Five-Year Retrospective Study.“TOSF”模式下糖尿病足治疗的疗效:一项五年回顾性研究。
Diabetes Metab Syndr Obes. 2024 May 2;17:1923-1939. doi: 10.2147/DMSO.S461112. eCollection 2024.
5
An Overview of Risk Factors for Diabetic Foot Amputation: An Observational, Single-centre, Retrospective Cohort Study.糖尿病足截肢危险因素概述:一项观察性、单中心、回顾性队列研究
touchREV Endocrinol. 2023 May;19(1):85-93. doi: 10.17925/EE.2023.19.1.85. Epub 2023 May 23.
6
Machine Learning Models for Predicting the Risk of Hard-to-Heal Diabetic Foot Ulcers in a Chinese Population.用于预测中国人群中难愈合糖尿病足溃疡风险的机器学习模型
Diabetes Metab Syndr Obes. 2022 Oct 29;15:3347-3359. doi: 10.2147/DMSO.S383960. eCollection 2022.
7
Analysis of routine blood markers for predicting amputation/re-amputation risk in diabetic foot.用于预测糖尿病足截肢/再次截肢风险的常规血液标志物分析
Int Wound J. 2020 Dec;17(6):1996-2004. doi: 10.1111/iwj.13491. Epub 2020 Oct 5.
8
The role of the platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in the prediction of length and cost of hospital stay in patients with infected diabetic foot ulcers: A retrospective comparative study.血小板与淋巴细胞比值及中性粒细胞与淋巴细胞比值在预测感染性糖尿病足溃疡患者住院时间和费用中的作用:一项回顾性比较研究。
Acta Orthop Traumatol Turc. 2020 Mar;54(2):127-131. doi: 10.5152/j.aott.2020.02.518.
9
Predictors of lower extremity amputation in patients with diabetic foot ulcer: findings from MEDFUN, a multi-center observational study.糖尿病足溃疡患者下肢截肢的预测因素:来自多中心观察性研究 MEDFUN 的结果。
J Foot Ankle Res. 2019 Jun 14;12:34. doi: 10.1186/s13047-019-0345-y. eCollection 2019.
10
Clinical and surgical characteristics of infected diabetic foot ulcers in a tertiary hospital of Mexico.墨西哥一家三级医院感染性糖尿病足溃疡的临床和外科特征
Diabet Foot Ankle. 2017 Sep 6;8(1):1367210. doi: 10.1080/2000625X.2017.1367210. eCollection 2017.

本文引用的文献

1
Risk factors for foot infections in individuals with diabetes.糖尿病患者足部感染的危险因素。
Diabetes Care. 2006 Jun;29(6):1288-93. doi: 10.2337/dc05-2425.
2
Treatment for diabetic foot ulcers.糖尿病足溃疡的治疗。
Lancet. 2005 Nov 12;366(9498):1725-35. doi: 10.1016/S0140-6736(05)67699-4.
3
Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial.厄他培南对比哌拉西林/他唑巴坦治疗糖尿病足感染(SIDESTEP):前瞻性、随机、对照、双盲、多中心试验
Lancet. 2005 Nov 12;366(9498):1695-703. doi: 10.1016/S0140-6736(05)67694-5.
4
Diabetic lower extremity infection: influence of physical, psychological, and social factors.糖尿病下肢感染:身体、心理和社会因素的影响
J Diabetes Complications. 2005 Mar-Apr;19(2):107-12. doi: 10.1016/j.jdiacomp.2004.06.002.
5
Guidelines for diabetic foot care: recommendations endorsed by the Diabetes Committee of the American Orthopaedic Foot and Ankle Society.糖尿病足护理指南:美国足踝矫形外科学会糖尿病委员会认可的建议
Foot Ankle Int. 2005 Jan;26(1):113-9. doi: 10.1177/107110070502600112.
6
Preventing foot ulcers in patients with diabetes.预防糖尿病患者足部溃疡
JAMA. 2005 Jan 12;293(2):217-28. doi: 10.1001/jama.293.2.217.
7
Diagnosis and treatment of diabetic foot infections.糖尿病足感染的诊断与治疗。
Clin Infect Dis. 2004 Oct 1;39(7):885-910. doi: 10.1086/424846. Epub 2004 Sep 10.
8
Costs of lower-extremity ulcers among patients with diabetes.糖尿病患者下肢溃疡的治疗费用。
Diabetes Care. 2004 Sep;27(9):2129-34. doi: 10.2337/diacare.27.9.2129.
9
A report from the international consensus on diagnosing and treating the infected diabetic foot.一份关于感染性糖尿病足诊断与治疗的国际共识报告。
Diabetes Metab Res Rev. 2004 May-Jun;20 Suppl 1:S68-77. doi: 10.1002/dmrr.453.
10
Peripheral arterial disease in people with diabetes.糖尿病患者的外周动脉疾病
Diabetes Care. 2003 Dec;26(12):3333-41. doi: 10.2337/diacare.26.12.3333.

糖尿病足感染治疗失败的临床预测因素:来自一项前瞻性试验的数据。

Clinical predictors of treatment failure for diabetic foot infections: data from a prospective trial.

作者信息

Lipsky Benjamin A, Sheehan Peter, Armstrong David G, Tice Alan D, Polis Adam B, Abramson Murray A

机构信息

Veterans Affairs Puget Sound Health Care System, University of Washington School of Medicine, Seattle, WA 98108-1597, USA.

出版信息

Int Wound J. 2007 Mar;4(1):30-8. doi: 10.1111/j.1742-481X.2006.00274.x.

DOI:10.1111/j.1742-481X.2006.00274.x
PMID:17425547
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7951310/
Abstract

To aid clinicians in selecting the appropriate approach for treating patients with diabetic foot infections, we investigated whether any baseline clinical findings predicted an unfavourable clinical outcome. Using data from a large, prospective treatment trial of diabetic foot infections (SIDESTEP), we assessed the association between clinical treatment failure and baseline history, physical and laboratory findings, by univariate and multivariate logistic regression analyses. Among 402 patients clinically evaluable 10 days after completing antibiotic therapy, baseline factors significantly (P < 0.05) associated by univariate analysis with treatment failure were 'severe' (versus 'moderate') University of Texas (UT) wound grade; elevated white blood cell count, C-reactive protein or erythrocyte sedimentation rate; high wound severity score; inpatient treatment; low serum albumin; male sex; and skin temperature of affected foot >10 degrees C above that of unaffected foot. By multivariate logistic regression only severe UT wound grade (odds ratio 2.1) and elevated white blood cell count [odds ratio 1.7 for a 1 standard deviation (2971 cells/mm(3)) increase] remained statistically significant. Clinical failure rates were 46% for patients with both risk factors compared with 10% for patients with no risk factors and 16-17% for patients with one risk factor. Increased white blood cell count and severe UT wound grade at baseline, but not other features, were significant independent and additive risk factors for clinical failure in patients treated for a diabetic foot infection.

摘要

为帮助临床医生选择治疗糖尿病足感染患者的合适方法,我们研究了是否有任何基线临床发现可预测不良临床结局。利用一项大型糖尿病足感染前瞻性治疗试验(SIDESTEP)的数据,我们通过单变量和多变量逻辑回归分析评估了临床治疗失败与基线病史、体格检查及实验室检查结果之间的关联。在完成抗生素治疗10天后可进行临床评估的402例患者中,单变量分析显示与治疗失败显著相关(P<0.05)的基线因素包括:德克萨斯大学(UT)伤口分级为“重度”(相对于“中度”);白细胞计数、C反应蛋白或红细胞沉降率升高;伤口严重程度评分高;住院治疗;血清白蛋白水平低;男性;患足皮肤温度比未患足高10摄氏度以上。通过多变量逻辑回归分析,仅重度UT伤口分级(比值比2.1)和白细胞计数升高[每增加1个标准差(2971个细胞/mm³),比值比为1.7]仍具有统计学意义。同时具有这两个危险因素的患者临床失败率为46%,无危险因素的患者为10%,具有一个危险因素的患者为16 - 17%。基线时白细胞计数升高和重度UT伤口分级,而非其他特征,是糖尿病足感染治疗患者临床失败的显著独立且相加的危险因素。